Investor Relations | Alnylam Pharmaceuticals, Inc.

Learn more about Alnylam’s response to COVID-19 ›

Webcast – Alnylam Announces Q2 2023 Financial Earnings
Watch Replay ›
LEARN MORE ›
Together will co-develop and co-commercialize investigational anti-hypertensive RNAi therapeutic

Alnylam & Roche Announce Zilebesiran Partnership
LEARN MORE ›
2023 marks our third year in a row on the Fast Company list

Alnylam Recognized as a Best Workplace for Innovators
Corporate Responsibility at Alnylam

We’ve published our third annual Corporate Responsibility Report
Read More ›
LEARN MORE ›
Positive results will inform continued clinical development in Alzheimer’s disease and cerebral amyloid angiopathy

ALN-APP Interim Phase 1 Clinical Data
Alnylam Publishes 2022 Annual Report

CEO Yvonne Greenstreet reflects on the next chapter in the RNAi Revolution
Read More ›
LEARN MORE ›
2022 marks second year in a row on the Fast Company list

Alnylam Named One of Fast Company's Most Innovative Companies for 2023
LEARN MORE ›
2023 marks third year in a row on Bloomberg’s List

Alnylam Named to Bloomberg’s Gender-Equality Index
LEARN MORE ›
Our efforts in ESG have earned us recognition from Newsweek

Alnylam Named One of America’s Most Responsible Companies

EVENTS & PRESENTATIONS

Aug 10, 2023

Canaccord Genuity 43rd Annual Growth Conference

Past Events ›

Aug 03, 2023

Alnylam Pharmaceuticals Q2 2023 Earnings Conference Call

Past Events ›

Jul 24, 2023

Alnylam Pharmaceuticals Conference Call to Discuss Roche Partnership

Past Events ›

View all events and presentations ›

2022 Annual Report

2023 Proxy Statement

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q2 2023 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

Corporate Responsibility VIEW PDF ›

View all resources and documents ›

PRESS RELEASES

Sep 13, 2023

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Sep 13, 2023

Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Sep 07, 2023

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

View all press releases ›